Stay updated with breaking news from Nasdaq apre. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Aprea Therapeutics, Inc. (NASDAQ:APRE – Free Report) – Analysts at Wedbush reduced their FY2028 earnings per share estimates for Aprea Therapeutics in a research report issued to clients and investors on Tuesday, May 14th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings of $0.77 per share for the year, down from […] ....
Aprea Therapeutics (NASDAQ:APRE – Free Report) had its price target boosted by Wedbush from $9.00 to $11.00 in a research note issued to investors on Wednesday morning, Benzinga reports. The firm currently has an outperform rating on the stock. Separately, HC Wainwright restated a buy rating and issued a $20.00 price target on shares of […] ....
Aprea Therapeutics, Inc. (NASDAQ:APRE – Get Free Report)’s share price traded down 4.9% on Monday . The company traded as low as $3.61 and last traded at $3.69. 2,872 shares traded hands during trading, a decline of 87% from the average session volume of 22,918 shares. The stock had previously closed at $3.88. Analyst Ratings […] ....
Aprea Therapeutics, Inc. (NASDAQ:APRE – Get Free Report) saw a large growth in short interest in June. As of June 30th, there was short interest totalling 25,600 shares, a growth of 161.2% from the June 15th total of 9,800 shares. Currently, 0.8% of the shares of the company are short sold. Based on an average […] ....